自动文章合并|自动图片压缩

content/newsList.md

 ---
 news:
 - title: 祝贺Alto Neuroscience登陆纽交所
+  titleEN: Congratulations to Alto Neuroscience Listed on the NYSE
   hide: false
   type: 医疗健康
-  createDate: 2024-02-05T09:33:35.144Z
+  typeEN: Healthcare
+  createDate: 2024-02-02T09:33:35.144Z
   abstract: >-
     2024年2月2日，精神领域精准药物研发公司Alto
     Neuroscience（以下简称“Alto”）成功登陆纽交所，股票代码为“ANRO”。此次Alto上市发行价为16美元/股，募集资金超1.29亿美元。高榕资本于2023年参与投资了Alto的C轮融资。
+  abstractEN: >-
+    Alto Neuroscience is a clinical-stage biopharmaceutical company with a
+    mission to redefine psychiatry by leveraging neurobiology to develop
+    personalized and highly effective treatment options.
   content: >-
     2024年2月2日，精神领域精准药物研发公司Alto
     Neuroscience（以下简称“Alto”）成功登陆纽交所，股票代码为“ANRO”。此次Alto上市发行价为16美元/股，募集资金超1.29亿美元。高榕资本于2023年参与投资了Alto的C轮融资。
@@ -54,6 +60,56 @@ news:
 
 
     ![](/static/img/alto祝贺海报.png)
+  contentEN: >-
+    On February 2, 2024, Alto Neuroscience, a precision medicine company focused
+    on the mental health sector, has successfully debuted on the New York Stock
+    Exchange (NYSE) under the ticker symbol "ANRO." The IPO was priced at $16
+    per share, raising over $129 million in funds. Notably, in 2023, Alto
+    received investment from Gaorong Ventures during its Series C financing
+    round.
+
+
+    Alto Neuroscience is a clinical-stage biopharmaceutical company with a
+    mission to redefine psychiatry by leveraging neurobiology to develop
+    personalized and highly effective treatment options.
+
+
+    ![](/static/img/alto-neuroscience.png)
+
+
+    Founded in 2019 by Dr. Amit Etkin, a psychiatry professor at Stanford
+    University, Alto leverages a profound understanding of brain functionality.
+    By adopting a differentiated drug development approach, Alto aims to
+    efficiently create precision drugs for mental health patients, avoiding
+    potentially lengthy and ineffective treatment processes. Traditional
+    psychiatric drug development often faces high failure rates at the clinical
+    stage due to a lack of understanding of how drugs affect the human brain.
+
+
+    Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing
+    EEG activity, neurocognitive assessments, wearable data, and other factors
+    to better identify which patients are more likely to respond to Alto product
+    candidates.
+
+
+    Currently, Alto has progressed five clinical-stage pipelines targeting
+    populations with specific brain biomarkers associated with MDD and
+    schizophrenia. These pipelines have undergone at least Phase I clinical
+    trials, demonstrating good safety and tolerability. The fastest advancing
+    candidates, ALTO-100 and ALTO-300, have successfully completed Phase IIa
+    trials with over 200 patients each and are swiftly progressing to Phase IIb.
+    ALTO-100 targets MDD patients with neural cognitive biomarkers, while
+    ALTO-300 targets MDD patients with EEG biomarkers. Furthermore, Alto plans
+    to initiate Phase II efficacy validation clinical trials for ALTO-101 and
+    ALTO-203 in the first half of 2024. These trials will respectively focus on
+    treating schizophrenic patients with cognitive impairments and MDD patients
+    experiencing pleasure loss.
+
+
+    In the healthcare sector, Gaorong Ventures seeks to identify and support
+    internationally innovative companies, continuing its investment in
+    outstanding enterprises across new drug development, medical devices,
+    digital health, and medical services.
   pic: /static/img/alto-neuroscience.png
   highLight: true
 - title: 关于冒用高榕资本名义的严正声明